RxDoctor Payments Data

Shravani Surakanti, MD

Internal Medicine · Baton Rouge, LANPI 1710327424

Payments from drug & device makers

$834in general payments, 2019–2025

Across 41 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$237
  • Johnson & Johnson$227
  • E.r. Squibb & Sons, L.L.C.$156
  • Acadia Pharmaceuticals Inc$143
  • Silk Road Medical, Inc.$47
  • Pfizer$23

What the payments were for

  • Food & beverage$74990%
  • Education$8510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$834 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$223,399
Medicare patients
554
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban520$153,705
JardianceEmpagliflozin160$49,013
TrulicityDulaglutide38$38,320
EntrestoSacubitril/Valsartan100$31,352
JanuviaSitagliptin Phosphate84$23,966
XareltoRivaroxaban72$20,675
TradjentaLinagliptin77$19,941
RestasisCyclosporine25$16,931
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc148$14,885
Tresiba Flextouch U-100Insulin Degludec21$14,074
SavellaMilnacipran Hcl43$13,556
FarxigaDapagliflozin Propanediol44$13,334
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,148
Atorvastatin Calcium721$11,189
Lantus SolostarInsulin Glargine,hum.Rec.Anlog157$10,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$153,705520 claims
Johnson & JohnsonXarelto$227$20,67572 claims
AstraZenecaFarxiga$237$13,33444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →